This Oral Solid Dosage Stock Rises 87% in 6 Months: What Is Fueling the Rally?

An oral solid dosage stock from the domestic pharma contract manufacturing space has turned into one of the sharpest recoveries on the small-cap board. This oral solid dosage stock gained approximately 87% in six months, moving from a depressed base in March 2026 to a fresh high in September 2026, among a screen of NSE small-cap stocks ranked by 6-month return, dated 24 September 2026.

The company behind this move is Innova Captab Ltd (NSE: INNOVACAP), a pharma CDMO that manufactures tablets, capsules, ointments and dry syrups for more than 350 domestic and export pharma brands out of its Baddi and Jammu facilities. Most of its output carries the labels of the pharma companies that commission it, which makes it one of the larger listed names focused on third-party formulation manufacturing in India.

Click Here – Get Free Investment Predictions

Which Oral Solid Dosage Stock Gave the Highest Return in 6 Months?

Innova Captab is the oral solid dosage stock that delivered the strongest six-month move in this screen, up approximately 87% between 24 March 2026 and 24 September 2026. The Innova Captab share price fell to about Rs 656 in late March 2026 before climbing steadily through the summer and rallying sharply in September, when it repeatedly hit new 52-week highs on heavy volume.

Here is how this oral solid dosage stock has moved across verified periods:

Period	Return (%)	Base Price	Latest Price
6 Months (24 Mar 2026 to 24 Sep 2026)	Approximately 87%	Rs 691.00	Rs 1,290.10
1 Month (24 Aug 2026 to 24 Sep 2026)	Approximately 21%	Rs 1,063.05	Rs 1,290.10
1 Year (24 Sep 2025 to 24 Sep 2026)	Approximately 52%	Rs 851.35	Rs 1,290.10

The one-year figure gives honest context. The share was already near Rs 851 in September 2025, then drifted down to about Rs 656 by March 2026 before this oral solid dosage stock began its rally. Roughly two-thirds of the twelve-month gain has come in the last six months, making this a recovery-and-breakout story rather than a smooth climb. Three and five-year returns are not shown because Innova Captab listed only in December 2023.

Why Did This Oral Solid Dosage Stock Rise 87% in Six Months?

This oral solid dosage stock rose 87% because four developments landed close together: a strong Q1 FY27 earnings beat, a ramp-up at a large new plant, a regulatory shift favouring compliant manufacturers, and a fresh capacity expansion approved by the board. Each of these four drivers behind the oral solid dosage stock is worth looking at in turn.

1. A Sharp Earnings Jump in Q1 FY27

Innova Captab reported Q1 FY27 revenue of approximately Rs 472.9 crore for the quarter ended 30 June 2026, up about 33% from Rs 356.0 crore a year earlier. The board approved these results on 11 August 2026, and this oral solid dosage stock moved up sharply in the sessions that followed. EBITDA rose to Rs 75.1 crore from Rs 56.6 crore, and net profit climbed to Rs 44.1 crore from Rs 31.0 crore, up about 42% year on year.

Metric	Q1 FY27 (Jun 2026)	Q1 FY26 (Jun 2025)	Change
Revenue	Rs 472.9 Cr	Rs 356.0 Cr	Up approximately 33%
EBITDA	Rs 75.1 Cr	Rs 56.6 Cr	Up approximately 33%
Net Profit	Rs 44.1 Cr	Rs 31.0 Cr	Up approximately 42%
EPS (Diluted)	Rs 7.71	Rs 5.42	Up approximately 42%

2. The Jammu Plant Is Finally Ramping Up

Innova Captab commissioned a Rs 450 crore-plus plant in Jammu in January 2025, but it ran at only 5 to 10% utilisation through FY26, generating about Rs 300 crore of revenue. Management now expects utilisation to rise to 40 to 50% over two to three years, a level that could eventually generate close to Rs 1,400 crore from that site alone. For this oral solid dosage stock, every point of added utilisation drops almost straight to margin, which is why the oral solid dosage stock has started pricing in the ramp-up early.

3. A Regulatory Tailwind From Tighter Schedule M Norms

India's revised Schedule M manufacturing norms, tightened after contamination cases, are pushing smaller pharma units to upgrade or shut down. A domestic brokerage cites estimates that over 60% of roughly 8,500 registered small and medium manufacturers could struggle to meet the new bar, and every exiting unit is a potential order shifting to a larger, compliant oral solid dosage stock such as Innova Captab.

4. Fresh Capacity Approved at Baddi

On 22 August 2026, the board approved a further Rs 45 crore for two new production lines at the existing Baddi facility, funded through internal accruals and bank credit. The move by this oral solid dosage stock signals confidence that demand from its client base can absorb more volume beyond what Jammu and Baddi already produce.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

Oral Solid Dosage Stock Financials: Quarterly and Yearly Trend

Revenue for this oral solid dosage stock has grown every quarter for five straight quarters, from Rs 356.0 crore in June 2025 to Rs 472.9 crore in June 2026, with profit usually growing faster than revenue.

Quarter	Revenue (Rs Cr)	EBITDA (Rs Cr)	Net Profit (Rs Cr)	Net Margin (%)
Jun 2025	356.0	56.6	31.0	8.82
Sep 2025	384.6	56.1	29.7	7.80
Dec 2025	451.9	71.1	42.2	9.36
Mar 2026	449.4	66.7	38.1	8.50
Jun 2026	472.9	75.1	44.1	9.37

On a full-year basis, revenue rose from Rs 1,255.7 crore in FY25 to Rs 1,637.4 crore in FY26, up approximately 30%. Net profit rose more slowly, from Rs 128.3 crore to Rs 140.9 crore, up about 10%, since margins were squeezed by the underutilised Jammu plant. The board later revised the audited FY26 numbers after flagging what it called an inadvertent, immaterial error; the corrected figures are used throughout. Return on equity is approximately 12.92%, and debt to equity has eased from 0.38 in FY24 to 0.32 now, giving this oral solid dosage stock room to fund its expansion without a large equity raise.

Is Institutional Money Backing This Oral Solid Dosage Stock?

Institutional ownership in this oral solid dosage stock is modest and promoter holding dominates. Promoters have held a steady 50.9% for five straight quarters, domestic institutions own about 20%, and foreign institutional ownership has shrunk from 0.7% in December 2024 to just 0.1% in December 2025. The table below tracks the trend in this oral solid dosage stock's ownership base:

Shareholder	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	50.9%	50.9%	50.9%	50.9%	50.9%
FIIs	0.7%	0.4%	0.2%	0.1%	0.1%
DIIs	20.0%	19.8%	19.7%	20.2%	20.2%
Public	28.4%	29.0%	29.2%	28.9%	28.8%

The unchanged promoter stake is a positive signal for the Innova Captab share price, since promoter selling often accompanies a sharp rally. Promoters filed a declaration in April 2026 confirming no encumbrance on their shares for FY26. Separately, about 4.37% of equity is held by debt trustee Vistra ITCL as loan collateral, unrelated to the promoter group and routine for rated corporate debt.

Key Risks Before Buying This Oral Solid Dosage Stock

The biggest risk to the Innova Captab share price is valuation after an 87% run. Innova Captab trades at a trailing PE of approximately 48.3 against an industry PE of about 38.3 and a price to book of roughly 6.8, so much of the growth story is already in the price.

Execution risk at Jammu: The bull case for this oral solid dosage stock leans on utilisation rising from single digits to 40 to 50% within a couple of years. Delays in client onboarding would directly hit the margin gains the market is pricing in.

Client concentration: As a third-party oral solid dosage stock, Innova Captab depends on repeat orders from a base of pharma brands rather than its own consumer product. A slowdown among a few large clients, or clients in-sourcing their own manufacturing, can hit revenue quickly.

Small-cap liquidity and volatility: With a market capitalisation of about Rs 7,436 crore and thin volumes versus large-cap pharma names, this oral solid dosage stock can swing sharply on modest order flow, and exiting a large position quickly may not be easy.

Accounting restatement: The board's revision of audited FY26 results for an inadvertent error, even if immaterial, is worth tracking in future filings for this oral solid dosage stock.

Regulatory and input-cost risk: The company remains exposed to drug price control changes, raw material price swings and periodic plant inspections.

Download the Univest iOS App or Univest Android App to track the Innova Captab share price live

Innova Captab Share: Analyst View

The analyst view on the Innova Captab share turned constructive ahead of the latest leg of the rally. A domestic brokerage initiated coverage in July 2026 with a buy rating, citing the Jammu ramp-up, the Schedule M tailwind and strong domestic pharma market growth as reasons to own this oral solid dosage stock.

Analysts are now watching three things: Jammu utilisation climbing past single digits, margins holding above 15% as new Baddi lines start up, and how the stock behaves once valuation catches up with growth.

Innova Captab Share Price Target

The latest verified domestic brokerage Innova Captab share price target is Rs 1,180, set in July 2026 on about 28 times FY28 estimated earnings. The Innova Captab share price has since moved past that level to around Rs 1,290, so no verified target above the current price is available. Investors are watching the 52-week high of Rs 1,353.50 as the near-term reference for this oral solid dosage stock instead.

Parameter	Figure
Innova Captab Share Price (24 Sep 2026)	Approximately Rs 1,290
Brokerage Target (Jul 2026)	Rs 1,180
Status vs CMP	Target already surpassed
52-Week High	Rs 1,353.50
52-Week Low	Rs 622.00
IPO Price (Dec 2023)	Rs 448 (upper band)

A share price target is only an estimate, not a guarantee. Fresh buyers of this oral solid dosage stock should watch actual quarterly execution rather than lean on a single target.

Other Stocks to Track From the Same Return Screen

Beyond this oral solid dosage stock, a screen of NSE small-cap stocks ranked by recent returns also includes related names such as Aequs with a 6-month return of 97.80%, KDDL at 91.12% and Ram Ratna Wires at 79.16%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this oral solid dosage stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

Innova Captab has gone from a depressed, range-bound oral solid dosage stock in March 2026 to one of the stronger small-cap movers of the last six months, helped by a Q1 FY27 earnings jump, an improving Jammu plant and a regulatory backdrop favouring larger, compliant manufacturers. The 87% move already prices in a fair amount of good news, so the next leg depends on whether Jammu utilisation and margins reach guided levels. This is informational analysis, not investment advice, and readers should verify current data and consult a SEBI-registered advisor before making any decision in this oral solid dosage stock.

Frequently Asked Questions

Which oral solid dosage stock rose approximately 87% in 6 months?

Ans. Innova Captab Ltd (NSE: INNOVACAP) is the oral solid dosage stock that gained approximately 87% between 24 March 2026 and 24 September 2026. It was among the strongest performers on a screen of NSE small-cap stocks ranked by 6-month return, dated 24 September 2026.

What does Innova Captab actually manufacture?

Ans. Innova Captab is a pharma contract manufacturer that makes tablets, capsules, ointments and dry syrups for more than 350 domestic and export brands from its Baddi and Jammu plants, mostly under clients' own labels. That is the core of this oral solid dosage stock story.

Why did this oral solid dosage stock rally in 2026?

Ans. The rally followed a Q1 FY27 profit jump of about 42% year on year, a gradual utilisation ramp-up at the new Jammu facility, a regulatory push under revised Schedule M norms favouring compliant manufacturers, and a fresh Rs 45 crore capacity expansion at the Baddi plant approved in August 2026.

What were Innova Captab Q1 FY27 results?

Ans. For the quarter ended June 2026, revenue was approximately Rs 472.9 crore, up about 33% year on year, and net profit was Rs 44.1 crore, up about 42% from Rs 31.0 crore. EBITDA rose to Rs 75.1 crore from Rs 56.6 crore.

Is this oral solid dosage stock overvalued after the rally?

Ans. It trades at a trailing PE of approximately 48.3 against an industry PE of about 38.3, so valuation sits above the sector average after the 87% six-month move, with much of the Jammu ramp-up story already priced into this oral solid dosage stock.

What is the Innova Captab share price target?

Ans. The latest verified domestic brokerage target is Rs 1,180, set in July 2026, and the Innova Captab share price has already moved past that to around Rs 1,290. No verified target above CMP exists, so the 52-week high of Rs 1,353.50 is the near-term reference for this oral solid dosage stock.

Has Innova Captab's promoter pledged any shares?

Ans. No. Promoters filed a declaration in April 2026 confirming no encumbrance on their shareholding for FY26. A separate 4.37% stake held by debt trustee Vistra ITCL as loan collateral is unrelated to the promoter group and routine for rated corporate debt.

When did Innova Captab list on the stock exchanges?

Ans. Innova Captab listed on NSE and BSE on 29 December 2023 after an IPO priced at Rs 426 to Rs 448 per share. That means this oral solid dosage stock does not yet have three-year or five-year price history, so only shorter verified periods are shown.